Literature DB >> 12853703

Expression and function of CD28 on Epstein-Barr virus-positive B cell lines and AIDS-associated non-Hodgkin's lymphoma cell lines.

Daniel Widney1, W John Boscardin, Arjang Kasravi, Otoniel Martínez-Maza.   

Abstract

CD28, which is expressed on most T cells, can provide a costimulatory signal during T cell activation. Although principally considered to be a T cell-associated molecule, CD28 has been seen to be expressed on mast cells and natural killer cells, as well as on plasma and myeloma cells, but not on cells representing earlier stages of B cell development. Here were report that CD28 was expressed on Epstein-Barr virus (EBV)-positive B lymphoblastoid and AIDS-associated non-Hodgkin's lymphoma cell lines. These cells also expressed the ligands for CD28, B7-1 and B7-2, but not CTLA-4. Furthermore, peripheral blood B cells infected with EBV ex vivo expressed CD28 after infection. Cross-linking with a stimulatory anti-CD28 antibody resulted in an increased expression of CD71 (transferrin receptor) or CD25 (interleukin-2 alpha receptor subunit). The addition of a blocking CTLA-4-Ig fusion protein, or antisense oligonucleotides for CD28, resulted in a decreased expression of these molecules. In 1 cell line, the addition of an anti-CD28 stimulatory antibody reduced Fas-induced apoptosis, and antisense oligonucleotide-induced inhibition of CD28 expression enhanced Fas-mediated apoptosis. Overall, these results suggest a role for CD28 and its ligands, B7-1 and B7-2, in homotypic interactions in EBV+ B cell lines, which may mediate cellular activation and/or viability. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853703     DOI: 10.1159/000071081

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  7 in total

1.  Immune Activation: Contribution to AIDS-Associated Non-Hodgkin Lymphoma.

Authors:  Marta Epeldegui; Otoniel Martínez-Maza
Journal:  For Immunopathol Dis Therap       Date:  2015

2.  CD40·FasL and CTLA-4·FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling.

Authors:  Ariel Orbach; Jacob Rachmilewitz; Noam Shani; Yonatan Isenberg; Miriam Parnas; Jui-Han Huang; Mark L Tykocinski; Michal Dranitzki-Elhalel
Journal:  Am J Pathol       Date:  2010-11-18       Impact factor: 4.307

Review 3.  HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.

Authors:  Marta Epeldegui; Elena Vendrame; Otoniel Martínez-Maza
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

4.  Efficacy of an Anti-transferrin Receptor 1 Antibody Against AIDS-related Non-Hodgkin Lymphoma: A Brief Communication.

Authors:  Tracy R Daniels-Wells; Daniel P Widney; Lai Sum Leoh; Otoniel Martínez-Maza; Manuel L Penichet
Journal:  J Immunother       Date:  2015-10       Impact factor: 4.456

5.  Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma.

Authors:  Daniel P Widney; Dorina Gui; Laura M Popoviciu; Jonathan W Said; Elizabeth C Breen; Xin Huang; Christina M R Kitchen; Juan M Alcantar; Jeffrey B Smith; Roger Detels; Otoniel Martínez-Maza
Journal:  AIDS Res Treat       Date:  2010-08-25

6.  Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.

Authors:  Nicole Caduff; Donal McHugh; Anita Murer; Patrick Rämer; Ana Raykova; Vanessa Landtwing; Lisa Rieble; Christian W Keller; Michael Prummer; Laurent Hoffmann; Janice K P Lam; Alan K S Chiang; Friedrich Raulf; Tarik Azzi; Christoph Berger; Tina Rubic-Schneider; Elisabetta Traggiai; Jan D Lünemann; Michael Kammüller; Christian Münz
Journal:  PLoS Pathog       Date:  2020-04-06       Impact factor: 6.823

7.  Levels of murine, but not human, CXCL13 are greatly elevated in NOD-SCID mice bearing the AIDS-associated Burkitt lymphoma cell line, 2F7.

Authors:  Daniel P Widney; Tove Olafsen; Anna M Wu; Christina M R Kitchen; Jonathan W Said; Jeffrey B Smith; Guadalupe Peña; Larry I Magpantay; Manuel L Penichet; Otoniel Martinez-Maza
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.